US Pharma MarketingZymeworks to acquire troubled biotech Theravance in $929M deal
Zymeworks to acquire Theravance Biopharma for $929M, gaining rights to COPD drug Yupelri Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA:…
Zymeworks is set to put Theravance Biopharma out of its misery, announcing on Monday that it will buy the biotech for $929 million upfront in cash.
In March, Theravance said it was shutting down its ...
Source: Endpoints News